Clinical trials have shown that E2F3 is overexpressed in advanced clear cell renal cell carcinoma (ccRCC), and there are multiple E2F3 binding sites in the promoter of HIF-2a. The gene discussed is E2F3; the disease is nonpapillary renal cell carcinoma.